Loading…
← CockpitCompetitor Analysis › ETRA Electra Therapeutics Inc.Open in the cockpit ↗

Electra Therapeutics Inc.ETRACompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Mkt cap
$530M
US dollars, full cap
Free float
61%
of shares outstanding
$/day
$2.85M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 10.2%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$8.43
1D+1.0%
1W-10.8%
1M-4.3%
3Mn/a
6Mn/a
YTDn/a
1Yn/a
ATR %12.7%
52w lowhigh45.6% off high

What Electra Therapeutics does

No business profile yet.

Electra Therapeutics at a glance

Size Electra Therapeutics (ETRA) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $530M, the 2634th largest of 3,085 United States companies the cockpit tracks. Shares closed at $8.43 on 18 Nov 2026.

Short interest Short interest is 0.8% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Electra Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024
Revenuen/a$0$0
Revenue growth———
Gross profitn/a-$61,000$0
EBITDAn/a-$61.8M-$26.3M
Net incomen/a-$62.0M-$24.8M
Free cash flown/a-$61.2M-$26.0M
Capital expendituren/a$733,000$0
Total debt$1.71M$2.09M$0

Quarterly statements and history in the cockpit →

Electra Therapeutics competitors and peer comparison

How Electra Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Electra Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureETRAPeer medianRank in peer set
1-month return-4.3%-7.2%7th highest of 20
Distance from 52-week high-45.6%-38.7%4th lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Electra Therapeutics ETRAUnited States$530Mn/an/an/an/an/an/a
Jinling Pharmaceutical 000919.SZChina$529M-15%-8%1%0.7×2.4%+5.0%
Supriya Lifescience SUPRIYA.NSIndia$529M-15%+23%26%5.5×28.2%+15.8%
Evonile Pharma EVONILE.NSIndia$529Mn/a-5%12%16.2×49.3%-1.5%
Chimin Health Management 603222.SSChina$533M-31%+1%-28%6.6×n/an/a
Senores Pharmaceuticals SENORES.NSIndia$538M+3%+40%24%7.4×n/an/a
Morepen Laboratories MOREPENLAB.NSIndia$542M+121%+30%11%2.2×n/an/a
Beijing Science Sun Pharmaceutical 300485.SZChina$517M-29%-11%-8%5.6×n/an/a
Xizang Weixinkang Pharmaceutical 603676.SSChina$513M-22%-8%16%2.3×-6.1%+9.6%
Jinhe Biotechnology 002688.SZChina$550M-19%+7%5%1.8×1.0%+9.7%
Egetis Therapeutics EGTX.STSweden$509M+76%+27%-645%71.0×n/an/a
Zeria Pharmaceutical 4559.TJapan$552M-12%+12%15%1.0×-12.3%+11.1%
Zevra Therapeutics ZVRAUnited States$552M-9%+75%31%2.4×-4.9%+51.6%
Boryung 003850.KSSouth Korea$554M-13%+6%6%0.9×-3.1%+12.6%
Aclaris Therapeutics ACRSUnited States$555M-23%-59%-1,412%69.1×n/an/a
Indaptus Therapeutics INDPUnited States$505M+147%n/an/an/an/an/a
Gujarat Themis Biosyn GUJTHEM.NSIndia$505M+2%+18%39%27.2×n/an/a
Tianjin Lisheng Pharmaceutical 002393.SZChina$557M-24%-3%7%1.2×-5.8%+4.1%
Shanghai Xiao Fang Pharmaceutical 603207.SSChina$503M-17%+10%39%4.8×-5.4%+7.6%
Gyre Therapeutics GYREUnited States$500M-28%+14%-18%4.0×n/an/a
Zhong Zhu Healthcare 600568.SSChina$562M-22%-6%-34%6.2×n/an/a

Questions

Which companies are Electra Therapeutics's closest peers?
The cockpit's peer set: Jinling Pharmaceutical (000919.SZ), Supriya Lifescience (SUPRIYA.NS), Evonile Pharma (EVONILE.NS), Chimin Health Management (603222.SS), Senores Pharmaceuticals (SENORES.NS), Morepen Laboratories (MOREPENLAB.NS), Beijing Science Sun Pharmaceutical (300485.SZ), Xizang Weixinkang Pharmaceutical (603676.SS).

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.